Anti-Cancer Medicine

DENOSUMAB DESCRIPTION : Xgeva & Prolia  injection is a trade name of denosumab and which belongs to type of monoclonal antibody. This drug is classified as a “bone-modifying agent” , it works as a RANK ligand (RANKL) inhibitor.  Xgeva & Prolia  injection which attach and repairs only certain cells in the body and help to protect healthy cells from destroy. INDICATION : Xgeva & Prolia  injection is indicated for the treatment of Osteoporosis occur in men and women (menopause stage) (end of menopause/ change of life), whose have severe problem of fractures increased or who failed to other medication of osteoporosis . MECHANISM OF ACTION :  Denosumab is decided to target RANKL (RANK ligand), a protein which act as the main signal to help bone removal/resorption. Some of the bone loss conditions, RANKL overcome the body's natural defense against bone eradication.  CONTRAINDICATIONS :  Denosumab  is contraindicated...

Denosumab Prolia & X geva  injection is a trade name of denosumab and which belongs to type of monoclonal antibody.This drug is classified as a “bone-modifying agent”, it works as a RANK ligand (RANKL) inhibitor. These injections which attach and repairs only certain cells in the body and help to protect healthy cells from destroy. INDICATION : It can be indicated for the treatment of Osteoporosis occur in and women (menopause stage) (end of menopause/ change of life), whose have severe problem of fractures increased or who failed to other medication of osteoporosis . Breast cancer in women whose taking certain treatment which make severe their risk of fractures and bone loss in men with prostate cancer. In adults and some adolescents with giant cell tumor of bone which cannot cured with surgery / surgery is not possible is treated with  Denosumab  injection. MECHANISM OF ACTION : Denosumab is decided to target RANKL (RANK ligand), a protein which a...

Secukinumab Description :   Secukinumab belongs to immuno suppressant which decrease the effects of a chemical substance in the body which can cause inflammation. Secukinumab  is required to treat moderate to severe plaque psoriasis (raised, silvery flaking of the skin) in adults. Indication :  Secukinumab  indicated for the treatment of following condition : Plaque Psoriasis, Psoriatic arthritis, Ankylosing spondylitis.. Mechanism Of Action :  Human IgG1 monoclonal antibody which selectively joins to and negate the pro inflammatory cytokine interleukin 17A (IL-17A) IL-17A is a normally appearing cytokine which is involved in normal inflammatory and immune responses and plays a key role in the pathogenesis of plaque psoriasis. Drug Interaction : Live vaccinations interaction with scapho 150mg should be avoided CYP450 substrates interaction with scapho injection may altered by increased levels of certain cytokines. Sid...